We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Global POC Diagnostics Market Driven by Growing Demand for Portable and Handheld Near-Patient Devices

By LabMedica International staff writers
Posted on 20 Dec 2022
Print article
Image: The global point-of-care diagnostics market is expected to surpass USD 93 billion by 2030 (Photo courtesy of Pexels)
Image: The global point-of-care diagnostics market is expected to surpass USD 93 billion by 2030 (Photo courtesy of Pexels)

Point of care (POC) diagnostics is medical diagnostic testing that is performed at or near the POC, and at the place and time of patient care. POC diagnostics includes blood glucose testing, rapid coagulation testing, drugs of abuse screening, blood gas and electrolyte analysis, quick cardiac marker diagnostic, pregnancy testing, infectious disease testing, cholesterol screening, hemoglobin diagnostic, etc. POC diagnostic testing differs from traditional diagnostics that is restricted to the laboratory. POC diagnostic tests can be performed at the bedside and brings the test immediately to the patient. POC diagnostic testing raises the likelihood of the patient receiving the test results quickly and improves clinical management. Portable and handheld instruments are used in POC diagnostics, enabling the test results to be shared quickly with the patients. It helps in the rapid detection of analytes near the patient, facilitates better disease diagnosis, monitoring, and management, and enables quick medical decisions. POC diagnostics plays a vital role in patient management by reducing the time to treatment.

The COVID-19 outbreak led to increased demand for POC diagnosis. This has been accompanied by the increasing incidence of chronic and infectious diseases globally. As a result, there has been growing demand for portable, transportable, and handheld devices that is fueling the growth of the POC diagnostics market. In addition, the increase in technological advancements has also contributed significantly to the market growth. The global POC diagnostics market is projected to grow at a CAGR of 11.1% from USD 39.91 billion in 2022 to USD 93.21 billion by 2030, driven by the rising incidence of chronic diseases such as cardiovascular disorders, diabetes, and infectious diseases, as well as an increasing geriatric population. These are the latest findings of Precedence Research (Ottawa, Canada), a market research firm.

Rapid technological advancements such as the emergence of cloud-based deep learning systems and chip technology miniaturization are expected to expand the applications of POC diagnostics. For instance, lab-on-a-chip technology is now used at the POC. The development of nanoparticle-based POC technology has also attracted the attention of the market players and helped doctors to take advantage of nanoparticles for the diagnosis of various chronic conditions. The market players are adopting modern technologies such as artificial intelligence (AI) to produce more efficient products and are focusing on integrating ELISA into products for diagnosing infectious diseases. However, the high cost of product development due to various technology areas depending upon the test type could hamper market growth.

Based on product, the blood glucose monitoring segment dominates the POC diagnostics market with the highest revenue share due to increasing demand for products for monitoring blood sugar levels and growing preference for home glucose testing. On the other hand, the infectious diseases segment is expected to register a promising CAGR during the forecast period due to the rising prevalence of various contagious diseases. Based on end user, the hospital bedside segment dominates the POC diagnostics market with the highest revenue share due to the rising prevalence of chronic diseases which require long-term care and frequent monitoring. The increasing awareness about the availability of cost-effective and highly innovative POC diagnostics creates a positive outlook for the market. On the other hand, the urgent care & retail clinics segment are expected to register a promising CAGR over the coming years due to the growing number of clinics and urgent care centers.

Based on region, North America dominated the global POC diagnostics market with the largest revenue share due to the high prevalence of lifestyle diseases, increasing awareness of self-testing and home care kits, and rapid technological advancements in the region. On the other hand, the Asia-Pacific market for POC diagnostics is expected to register a promising CAGR during the forecast period due to the increasing number of market players and growing use of POC diagnostics in the developing countries.

Related Links:
Precedence Research 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.